References
- Marttila RJ, Arstila P, Nikoskelainen J, et al: Viral antibodies in the sera from patients with Parkinson disease. Eur Neurol 15:25–33, 1977
- Lycke E, Roos BE: Some virological and biochemical aspects of the pathogenesis of Parkinson's disease. In Gillingham FJ, Donaldson IM: Symposium on Parkinson's Disease, May 1968. New York, Churchill Livingstone, Medical Division of Longman Inc, 1969, pp 16–19
- Davidowitz S, Zamir R. Kott E: HLA antigens in Parkinson's disease. In den Hartog Jager WA, Bruyn GW, Heijstee AP: Proceedings of 11th World Congress of Neurology, September 11–16, 1977. New York, Elsevier North-Holland, Inc, 1977, p 126
- Foley JM, Baxter D: On the nature of pigment granules in the cells of the locus coeruleus and substantia nigra. J Neuropathol Exp Neurol 17:586–598, 1958
- Lloyd DG, Davidson L, Hornykiewicz O: Metabolism of levodopa in the human brain. In Calne DB (Editor): Progress in the Treatment of Parkinsonism. Advances in Neurology series, vol 3. New York, Raven Press, 1973, pp 173–188
- Tatton WG, Lee RG: Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients. Brain Res 100:671–676, 1975
- Hoehn MM, Yahr MD: Parkinsonism: Onset, progression, and mortality. Neurology 17:427–442, 1967
- Marttila RJ, Rinne UK: Natural course of Parkinson's disease. Inden Hartog Jager et al,3 p 251
- Yahr MD: Evaluation of long-term therapy in Parkinson's disease. In Birkmayer W, Hornykiewicz O: Advances in Parkinsonism. Basel, Switzerland, Editiones Roche, 1976, pp 435–443
- Kartzinel R, Calne DB: Studies with bromocriptine. I. 'On-off phenomena. Neurology 26:508–510, 1976
- Birkmayer W, Riederer P, Youdim MB, et al: Potentiation of anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. In Birkmayer, Homykiewicz,9 pp 381–403